Affimed to Present at Upcoming Investor Conferences

Press Release - September 1, 2016

Download Press Release

Heidelberg, Germany, September 1, 2016 – Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, announced today that Dr. Adi Hoess, CEO, will present at two upcoming investor conferences.

Credit Suisse Antibody Day
Date: Wednesday, September 7, 2016
Time: 10:40 a.m. ET
Location: New York, NY

2016 Wells Fargo Healthcare Conference
Date: Thursday, September 8, 2016
Time: 1:10 p.m. ET
Location: Boston, MA

About Affimed N.V.

Affimed (Nasdaq: AFMD) engineers targeted immunotherapies, seeking to cure patients by harnessing the power of innate and adaptive immunity (NK- and T-cells). We are developing single and combination therapies to treat cancers and other life-threatening diseases. For more information please visit www.affimed.com.

Affimed IR Contact

Caroline Stewart, Head IR
Phone: +1 347 394 6793
E-Mail: email hidden; JavaScript is required or email hidden; JavaScript is required

Affimed Media Contact

Anca Alexandru, Head of Communications, EU IR
Phone: +49 6221 64793341
E-Mail: email hidden; JavaScript is required

We use cookies to give you the best experience on our website. By continuing to use it, you agree with it.

Okay